Targeted therapies for targeted populations: Anti-EGFR treatment for EGFR amplified gastroesophageal adenocarcinoma.

about

What's New in Gastric Cancer: The Therapeutic Implications of Molecular Classifications and Future Perspectives

P2860

Q57159608-CB4D53E2-C4B6-4290-951E-9C95583121EB

P2860

Targeted therapies for targeted populations: Anti-EGFR treatment for EGFR amplified gastroesophageal adenocarcinoma.

Item

http://www.wikidata.org/entity/Q49961144

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Targeted therapies for targete ...... stroesophageal adenocarcinoma.

@en

Targeted therapies for targete ...... stroesophageal adenocarcinoma.

@nl

type

Item

label

Targeted therapies for targete ...... stroesophageal adenocarcinoma.

@en

Targeted therapies for targete ...... stroesophageal adenocarcinoma.

@nl

prefLabel

Targeted therapies for targete ...... stroesophageal adenocarcinoma.

@en

Targeted therapies for targete ...... stroesophageal adenocarcinoma.

@nl

P1476

Targeted therapies for targete ...... stroesophageal adenocarcinoma.

@en

P2093

Alexa Schrock

http://www.w3.org/2001/XMLSchema#string

Daniel V T Catenacci

http://www.w3.org/2001/XMLSchema#string

David Xu

http://www.w3.org/2001/XMLSchema#string

Emily O'Day

http://www.w3.org/2001/XMLSchema#string

Fabiola Cecchi

http://www.w3.org/2001/XMLSchema#string

Heewon A Kwak

http://www.w3.org/2001/XMLSchema#string

John Hart

http://www.w3.org/2001/XMLSchema#string

Leah Chase

http://www.w3.org/2001/XMLSchema#string

Lindsay Alpert

http://www.w3.org/2001/XMLSchema#string

Namrata Setia

http://www.w3.org/2001/XMLSchema#string

P2860

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence.

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

P31

scholarly article

P356

10.1158/2159-8290.CD-17-1260

http://www.w3.org/2001/XMLSchema#string

P577

2018-02-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29449271

http://www.w3.org/2001/XMLSchema#string

P921

adenocarcinoma

P932

5984701

http://www.w3.org/2001/XMLSchema#string

Targeted therapies for targeted populations: Anti-EGFR treatment for EGFR amplified gastroesophageal adenocarcinoma.

about

P2860

P2860

Targeted therapies for targeted populations: Anti-EGFR treatment for EGFR amplified gastroesophageal adenocarcinoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P31

P356

P577

P698

P921

P932